<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">31783737</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2377</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC neurology</Title>
          <ISOAbbreviation>BMC Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>304</StartPage>
          <MedlinePgn>304</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">304</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-019-1542-9</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in cancer patients. PLE is difficult to diagnose and presents a variable response to treatment, depending on the characteristics of the tumor and neuronal autoantibodies.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 64-year-old, Caucasian, non-smoker man presented with a rapidly developing cognitive impairment, personality change, spatial disorientation, and short-term memory loss associated with anorexia and cervical and inguinal lymph nodes. The <sup>18</sup>F-FDG PET scan documented intensely hypermetabolic lymph nodes, which histologically corresponded to a metastasis from a small cell neuroendocrine carcinoma. The brain MRI revealed a high T2-weighted FLAIR signal of the hippocamps, consisted with a PLE. The presence of anti-neuronal Hu antibodies confirmed the diagnosis. The patient underwent plasmapheresis, associated to a systemic chemotherapy resulting in a partial and temporary improvement of the neurological symptoms. Four cycles of intravenous immunoglobulins were also necessary. After six cures of chemotherapy, the lymph node metastases regressed. However, a new anorectal lesion was detected and was histologically confirmed as a primary small cell neuroendocrine carcinoma, which was treated with concomitant chemoradiotherapy. At the end of this treatment, the patient showed a rapid tumor progression leading to his death.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case highlights the rare entity, PLE, which is difficult to diagnose and manage. In addition, this is the first published case of PLE associated with an anorectal small cell neuroendocrine carcinoma, which appeared after completion of systemic chemotherapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Longo</LastName>
            <ForeName>Raffaele</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-6090-2012</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France. r.longo@chr-metz-thionville.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wagner</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Savenkoff</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Castaing</LastName>
            <ForeName>Mathilde Chastenet</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desiro</LastName>
            <ForeName>Guillaume</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tubail</LastName>
            <ForeName>Zead</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hennequin</LastName>
            <ForeName>Laurent</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Radiology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahmoud</LastName>
            <ForeName>Sinan Ben</ForeName>
            <Initials>SB</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nuclear Medecine, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marcon</LastName>
            <ForeName>Nathalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pathology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quetin</LastName>
            <ForeName>Philippe</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Radiotherapy, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Campitiello</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Plastino</LastName>
            <ForeName>Francesca</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Neurol</MedlineTA>
        <NlmUniqueID>100968555</NlmUniqueID>
        <ISSNLinking>1471-2377</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>BMC Neurol. 2022 Mar 8;22(1):81</RefSource>
          <PMID Version="1">35260083</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018278" MajorTopicYN="N">Carcinoma, Neuroendocrine</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018288" MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020363" MajorTopicYN="N">Limbic Encephalitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic</Keyword>
        <Keyword MajorTopicYN="N">Small cell carcinoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31783737</ArticleId>
        <ArticleId IdType="pmc">PMC6884799</ArticleId>
        <ArticleId IdType="doi">10.1186/s12883-019-1542-9</ArticleId>
        <ArticleId IdType="pii">10.1186/s12883-019-1542-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Corsellis JA, Goldberg GJ, Norton AR. “Limbic encephalitis” and its association with carcinoma. Brain. 1968;91(3):481–496. doi: 10.1093/brain/91.3.481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/91.3.481</ArticleId>
            <ArticleId IdType="pubmed">5723018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:22. doi: 10.1186/1750-1172-2-22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1750-1172-2-22</ArticleId>
            <ArticleId IdType="pmc">PMC1868710</ArticleId>
            <ArticleId IdType="pubmed">17480225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al.  A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi: 10.1016/S1474-4422(15)00401-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J. CNS autoimmunity: new findings and pending issues. Lancet Neurol. 2012;11(1):17–19. doi: 10.1016/S1474-4422(11)70280-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(11)70280-0</ArticleId>
            <ArticleId IdType="pmc">PMC3723139</ArticleId>
            <ArticleId IdType="pubmed">22172617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grativvol RS, Cavalcante WCP, Castro LHM, Nitrini R, Simabukuro MM. Updates in the diagnosis and treatment of paraneoplastic neurologic syndromes. Curr Oncol Rep. 2018;20(11):92. doi: 10.1007/s11912-018-0721-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11912-018-0721-y</ArticleId>
            <ArticleId IdType="pubmed">30415318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495. doi: 10.1097/CCO.0000000000000222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCO.0000000000000222</ArticleId>
            <ArticleId IdType="pmc">PMC4640358</ArticleId>
            <ArticleId IdType="pubmed">26335665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen K, Xu Y, Guan H, Zhong W, Chen M, Zhao J, et al.  Paraneoplastic limbic encephalitis associated with lung cancer. Sci Rep. 2018;8(1):6792. doi: 10.1038/s41598-018-25294-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-25294-y</ArticleId>
            <ArticleId IdType="pmc">PMC5931551</ArticleId>
            <ArticleId IdType="pubmed">29717222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin KJ, Ji YI. Anti-Hu antibody-mediated limbic encephalitis associated with cervical cancer: A case report. J Obstet Gynaecol Res. 2018;44(6):1181–1184. doi: 10.1111/jog.13619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jog.13619</ArticleId>
            <ArticleId IdType="pubmed">29607578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue T, Kanno R, Moriya A, Nakamura K, Watanabe Y, Matsumura Y, et al.  A case of paraneoplastic limbic encephalitis in a patient with invasive thymoma with anti-glutamate receptor antibody-positive cerebrospinal fluid: a case report. Ann Thorac Cardiovasc Surg. 2018;24(4):200–204. doi: 10.5761/atcs.cr.17-00135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5761/atcs.cr.17-00135</ArticleId>
            <ArticleId IdType="pmc">PMC6102601</ArticleId>
            <ArticleId IdType="pubmed">29269707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi M, Nishioka K, Takanashi M, Hattori A, Shojima Y, Hayashida A, et al.  Anti-NMDA receptor encephalitis due to large-cell neuroendocrine carcinoma of the uterus. J Neurol Sci. 2017;383:72–74. doi: 10.1016/j.jns.2017.10.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2017.10.024</ArticleId>
            <ArticleId IdType="pubmed">29246628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastuszak Ż, Stępień A, Tomczykiewicz K, Piusińska-Macoch R, Kordowska J, Galbarczyk D, et al.  Limbic encephalitis - a report of four cases. Cent Eur J Immunol. 2017;42(2):213–217. doi: 10.5114/ceji.2017.69365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5114/ceji.2017.69365</ArticleId>
            <ArticleId IdType="pmc">PMC5573896</ArticleId>
            <ArticleId IdType="pubmed">28860940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci. 2014;21(5):722–730. doi: 10.1016/j.jocn.2013.07.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2013.07.017</ArticleId>
            <ArticleId IdType="pubmed">24246947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt SL, Schmidt JJ, Tolentino JC, Ferreira CG, de Almeida SA, Alvarenga RP, et al.  Cholangiocarcinoma associated with limbic encephalitis and early cerebral abnormalities detected by 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography-positron emission tomography: a case report. J Med Case Reports. 2016;10:200. doi: 10.1186/s13256-016-0989-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13256-016-0989-1</ArticleId>
            <ArticleId IdType="pmc">PMC4955157</ArticleId>
            <ArticleId IdType="pubmed">27439460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goffin KE, Ooms D, Ahmad R, Demaerel P, Van Paesschen W, Van Laere K, et al.  Metabolic-structural concordance in paraneoplastic limbic encephalitis. Eur J Nucl Med Mol Imaging. 2016;43(5):994–995. doi: 10.1007/s00259-015-3298-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-015-3298-9</ArticleId>
            <ArticleId IdType="pubmed">26743896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cózar Santiago Mdel P, Sanchez Jurado R, Sanz Llorens R, Aguilar Barrios JE, Ferrer Rebolleda J. Limbic Encephalitis diagnosed with 18F-FDG PET/CT. Clin Nucl Med. 2016;41(2):e101–e103. doi: 10.1097/RLU.0000000000001076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0000000000001076</ArticleId>
            <ArticleId IdType="pubmed">26571448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Rocha AJ, Nunes RH, Maia AC, Jr, do Amaral LL. Recognizing autoimmune-mediated encephalitis in the differential diagnosis of limbic disorders. AJNR Am J Neuroradiol. 2015;36(12):2196–2205. doi: 10.3174/ajnr.A4408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3174/ajnr.A4408</ArticleId>
            <ArticleId IdType="pmc">PMC7964266</ArticleId>
            <ArticleId IdType="pubmed">26381566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quartuccio N, Caobelli F, Evangelista L, Alongi P, Kirienko M, De Biasi V, et al.  The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature. J Neuroimmunol. 2015;284:44–48. doi: 10.1016/j.jneuroim.2015.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.05.002</ArticleId>
            <ArticleId IdType="pubmed">26025057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014;35(10):1038–1046. doi: 10.1097/MNM.0000000000000163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MNM.0000000000000163</ArticleId>
            <ArticleId IdType="pubmed">25023997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260(11):2744–2753. doi: 10.1007/s00415-013-7048-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-013-7048-2</ArticleId>
            <ArticleId IdType="pubmed">23900756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano Vicente J, García Bernardo L, Durán Barquero C, Infante Torre JR, Rayo Madrid JI, Domínguez Grande ML. Brain metabolic changes in limbic encephalitis evidenced by 18FDG PET. Correlation with symptomatology. Rev Esp Med Nucl Imagen Mol. 2013;32(3):201–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23266009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher RE, Patel NR, Lai EC, Schulz PE. Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med. 2012;37(9):e213–e218. doi: 10.1097/RLU.0b013e31824852c7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/RLU.0b013e31824852c7</ArticleId>
            <ArticleId IdType="pubmed">22889795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim TJ, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, et al.  Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol. 2014;270(1–2):45–50. doi: 10.1016/j.jneuroim.2014.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2014.02.011</ArticleId>
            <ArticleId IdType="pubmed">24662003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurotherapeutics. 2016;13(1):147–162. doi: 10.1007/s13311-015-0410-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0410-6</ArticleId>
            <ArticleId IdType="pmc">PMC4720680</ArticleId>
            <ArticleId IdType="pubmed">26692392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grisold W, Giometto B, Vitaliani R, Oberndorfer S. Current approaches to the treatment of paraneoplastic encephalitis. Ther Adv Neurol Disord. 2011;4(4):237–248. doi: 10.1177/1756285611405395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756285611405395</ArticleId>
            <ArticleId IdType="pmc">PMC3131173</ArticleId>
            <ArticleId IdType="pubmed">21765874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–854. doi: 10.4065/mcp.2010.0099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/mcp.2010.0099</ArticleId>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinsella JA, Irani SR, Hollingsworth R, O'Shaughnessy D, Kane P, Foster M, et al.  Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience. JRSM Open. 2018;9(9):1–5. doi: 10.1177/2054270418793021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/2054270418793021</ArticleId>
            <ArticleId IdType="pmc">PMC6122256</ArticleId>
            <ArticleId IdType="pubmed">30202534</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
